CNBC caught up with Biogen CEO George Scangos to discuss where he leaves the big biotech after six years at the helm. » Read More
U.S. stocks closed more than 1 percent lower Wednesday, despite higher oil prices, as disappointing quarterly reports weighed and the Fed statement renewed concerns about global economic growth.
U.S. stock index futures pointed to a lower open on Wednesday as low oil prices and earnings reports weighed on stocks ahead of the expected release of the Fed meeting statement in the afternoon.
Biogen's quarterly profit breezed past Wall Street's estimates, driven by higher demand for its key oral multiple sclerosis drug Tecfidera.
While the biotech sector has been under fire for high drug prices, Biotech CEO says that it brings innovations.
RBC Capital Markets analyst Michael Yee says there are three biotech stocks to own next year no matter how the sector performs in 2016.
Uri Gruenbaum, CEO of TipRanks, listed the top 10 biotech analysts on Wall Street based on the returns they've generated since 2009.
“Mad Money” host Jim Cramer is telling investors which stock is headed higher for the long-term.
Jim Cramer prepares investors for the biotech group to come roaring back in 2016, and shares his top picks.
Jim Cramer looks at the stock market like a card game, and investors just aren't dealing with the cards they have right now.
Mark Newton, chief technical analyst at Greywolf Execution Partners, shares his top investment idea for the months ahead.
Jim Cramer says this week was the most amazing transformation he has ever seen before. But can the bull continue to dance?
Ken Frazier discussed drug pricing with the president, and he believes many in Washington have a "rational" view of the situation.
CEO John Challenger says that even though job cuts are higher this year, lower jobless claims could mean the laid-off are transitioning quickly.
Biogen says it's cutting about 11 percent of its workforce and ending some development programs in a restructuring aimed to save $250 million a year.
CNBC's Meg Tirrell reports Biogen tops Street estimates and announces a restructuring plan that includes cutting the workforce and ending some pipeline programs.
The "Fast Money" traders gave their final thoughts of the day.
The "Halftime Report" traders give their top trades.
With many companies set to report earnings this week, one name in particular could be a make or break moment for biotech.
So far the earnings season has been lackluster, and some high-profile warnings have already given investors pause.
Jim Cramer sees growth starved investors searching for growth anywhere they can. That means a massive ephemeral rotation of stocks.